Prof Ian Frazer elected to Australian Academy of Science council

Friday, 16 December, 2011

Professor Ian Frazer, who was named Australian of the Year in 2006 for his development of the human papillomavirus (HPV) cervical cancer vaccines, has become one of the most recent members of the Australian Academy of Science (AAS), alongside a Nobel Laureate, a Eureka prize winner and a pioneer in mathematics.

“Election to council of the Australian Academy of Science is an honour,” Professor Frazer said. “It’s an opportunity to help shape the direction of our peak Australian scientific society at a time when science as a discipline is more important than ever in determining how society develops - and yet more challenged than ever for status within society.”

Professor Suzanne Cory, President of the Academy, said she is delighted to have such high-calibre new members join the council and looks forward to welcoming them at the annual general meeting at the Shine Dome on Thursday 4 May 2012.

The Australian Academy of Science is a Fellowship of the country’s leading researchers that works to promote and engage national and international communities with Australian science. The AAS was founded in 1954 by Australian Fellows of the Royal Society of London and modelled on the same principle and values. The Fellowship of the Academy comprises 450 of Australia’s top scientists, distinguished in the physical and biological sciences and their applications.

Professor Ian Frazer is joined by Professor Brian Schmidt, Nobel Laureate in physical sciences; Professor Nalini Joshi, a mathematics professor at The University of Sydney; CSIRO climate specialist Professor Michael Raupach and ecologist Professor Richard Shine, also from The University of Sydney.

Related News

QIMR Berghofer signs strategic partnership with Nakanoshima Qross

QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd